

S1 Table. Clinicodemographic characteristics of the patients, initial gastric cancer stage, and treatments by institution

	Y-cohort (n=439)	S-cohort (n=351)	p-value
Age (yr)	57.19±12.45	57.17±12.64	0.981
Sex			0.65
Male	293 (66.7)	228 (65.0)	
Female	146 (33.3)	123 (35.0)	
Serosa invasion			<0.001
Negative	115 (26.2)	240 (68.4)	
Positive	324 (73.8)	111 (31.6)	
LN metastasis			0.696
Negative	34 (7.7)	30 (8.5)	
Positive	405 (92.3)	321 (91.5)	
TNM stage			<0.001
II	76 (17.3)	112 (31.9)	
III	363 (82.7)	239 (68.1)	
Lauren classification			0.159
Intestinal	153 (34.9)	140 (39.9)	
Diffuse/mixed	286 (65.1)	211 (60.1)	
Tumor location			0.127
UB/Whole	82 (18.7)	51 (14.5)	
MB/LB	357 (81.3)	300 (85.5)	
MSI/MMR			0.026
MSS/pMMR	412 (93.8)	314 (89.5)	
MSI-H/dMMR	27 (6.2)	37 (10.5)	
Adjuvant CTx.‡			<0.001
No	84 (19.4)	130 (37.0)	
Yes	349 (80.6)	221 (63.0)	
Interval to recurrence			0.014
< 1 yr	195 (44.4)	127 (36.2)	
≥ 1 yr, < 2 yr	133 (30.3)	104 (29.6)	
≥ 2 yr	111 (25.3)	120 (34.2)	
Type of recurrence			0.039
Locoregional	76 (17.3)	56 (16.0)	
Hematogenous	92 (21.0)	62 (17.3)	
Peritoneum	175 (39.9)	161 (45.9)	
Any combination	75 (17.1)	67 (19.1)	
Krukenberg only	21 (4.8)	5 (1.4)	
CTx after recurrence^{a)}			<0.001
No	100 (23.1)	165 (51.4)	
Yes	333 (76.9)	156 (48.6)	

LN, lymph node; UB, upper body; MB, mid-body; LB, lower body; MSI, microsatellite

instability; MMR, mismatch repair; MSS, microsatellite stable; pMMR, proficient mismatch repair; MSI-H, microsatellite instability high; dMMR, deficient mismatch repair; CTx, chemotherapy. ^{a)}Information was incomplete in some patients because of transfer to another hospital, loss to follow-up, and unclear medical records.